Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · Feb 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called bicyclol to see how well it works for patients who have experienced liver injury caused by cancer treatments (also known as antineoplastic drugs). The goal is to understand how effective bicyclol is and what factors may influence the results of the treatment. The trial is currently looking for participants of all ages who have been diagnosed with acute liver injury linked to these anti-cancer drugs.

To be eligible for the trial, participants must have liver injury that is confirmed to be in the acute phase and must have a specific score (called the RUCAM assessment scale) showing that their liver injury is related to the treatment. Participants will need to take bicyclol tablets and provide informed consent before joining. However, individuals whose liver injury is caused by other medications, pregnant or breastfeeding women, and women who can become pregnant and are planning to conceive are not eligible for this trial. If you join, you can expect to receive treatment with bicyclol and be monitored for your progress throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The acute liver injury caused by anti-tumor drugs
• • 2. The RUCAM assessment scale ≥6
• • 3. The liver injury must in the acute phase
• • 4. Must be treated with bicyclol tablets
• • 5. Must sign informed consent -
• Exclusion Criteria:
• • 1. This acute liver injury caused by non-anti-tumor drugs
• • 2. Pregnant women
• • 3. Lactating women
• • 4. Childbearing age women are plan to conceive